$CELC 8-K/A SEC Filings

Filed On	Filing
15 Jul 2026	8-K/A: Regulation FD Disclosure; Other Events Celcuity Announces FDA Approval of REVTORPYK™ (gedatolisib) for the Treatment of HR+/HER2-, PIK3CA Wild-Type Locally Advanced or Metastatic Breast Cancer
20 May 2026	8-K/A: Departure/Election of Directors or Officers; Compensation Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
09 Nov 2022	8-K/A: Departure/Election of Directors or Officers; Compensation Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Comments